Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
Category: #health  By Pankaj Singh  Date: 2019-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.

Senseonics Holdings, Inc., a US-based medical device startup company recently announced that users of its Eversense CGM (continuous glucose monitoring) system can now use the new Eversense CGM mobile application for dosing insulin based on the readings from their Eversense System without requiring to perform a validating blood-glucose fingerstick measurement test.

For the record, Senseonics Holdings, is a medical technology pioneering the development, as well as commercialization, of the only long-term implantable CGM (continuous glucose monitoring) system for diabetic population.

The Eversense continuous glucose monitoring system comprises of a fluorescence sensor, a smart transmitter that is worn over the sensor to aid data communication, and lastly a mobile app for displaying glucose trends, values and alerts. The system does not only feature the first long-term, first implantable continuous glucose monitoring sensor but is also the first to include a smart transmitter, which provides wearers with subtle on-body vibratory alerts for low and high glucose levels.

In a brief in-office procedure,  health care providers can insert this sensor subcutaneously in the upper arm of the patient. The systems can be recharged, removed, or re-attached to the skin without discarding the sensor.

Tim Goodnow, President & CEO at Senseonics was reportedly quoted saying that since new Eversense app is available from the Google Play and Apple App stores, the users in the U.S. can take full advantage of being in a position to make treatment decisions without the need to test their blood glucose levels. He added saying that only after a year of entering the market, the company has made a remarkable achievement in the form of the new enhanced user experience by providing this updated indication in the Eversense technology.

Francine R. Kaufman, Endocrinologist, MD, CMO & Board member at Senseonics stated that Eversense users will now have the added benefit with the Eversense app of not having to interrupt their daily activities like eating or exercising for fingerstick before taking insulin.
 

Source Credit: https://www.senseonics.com/investor-relations/news-releases/2019/12-02-2019-210406927



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...